topics / weight management
Tagged weight management.
- 6/10 · Preliminary Amycretin An investigational single-molecule GLP-1 and amylin receptor agonist from Novo Nordisk with eye-catching early-phase weight-loss data, but no completed Phase 3 trials and no approval anywhere.
- 7/10 · Moderate Cagrilintide: A Long-Acting Amylin Analog with Strong Combination Data and Thin Standalone Evidence Cagrilintide is an investigational once-weekly amylin analog from Novo Nordisk. The robust human data are for the CagriSema combination, not the drug alone.
- 9/10 · Strong CagriSema An investigational once-weekly fixed combination of cagrilintide (an amylin analog) plus semaglutide (a GLP-1 drug) with large peer-reviewed Phase 3 weight-loss data, but no approval yet and a failed head-to-head against tirzepatide.
- 9/10 · Strong Orforglipron An oral, non-peptide (small-molecule) GLP-1 receptor agonist, FDA-approved in April 2026 as Foundayo for chronic weight management. It is a once-daily pill with no food or timing restrictions — not a peptide, and not an injectable.
- 7/10 · Moderate VK2735 (Viking) VK2735 is an investigational dual GLP-1/GIP receptor agonist from Viking Therapeutics being studied for obesity and metabolic disease. Phase 2 data are promising but it is not approved anywhere, and long-term safety is unknown.